Available Pipelines
Pipeline | Therapies | Target | Indication | Stage |
PAS-001 | CAR-T | NKG2DL | Glioblastoma, Colorectal Cancer, Hepatocellular Carcinoma |
IND approval in China |
PAS-002 | CAR-T | NKG2DL, CLDN18.2 | Pancreatic Cancer, Gastric Cancer |
Investigator-initiated clinical trials* (Pre-IND) in China |
PAS-003 | CAR-T | NKG2DL, CD33 | Acute Myeloid Leukemia |
Preclinical research in China |
PAS-009 | CAR-T | Mesothelin | Recurrent Ovarian Carcinoma |
IND approval in China |
PAS-010 | CAR-T | Mesothelin | Advanced Ovarian Carcinoma |
IND approval in China |
PAS-011 | CAR-T | CD19 | (R/R) B-ALL |
NDA approved (NMPA) |
*Investigator-initiated clinical trials (IIT) in China are conducted before IND application and support drug development.
Contact Us For More Details
We have basic information for all the pipelines listed above, including modalities, targets, indications, safety and efficacy data, and clinical data. Should you be interested, please get in touch with us and ask for more details.